Roots Analysis Market Research Overview
In 2018, it was estimated that the availability of low-cost, generic versions of pharmaceutical interventions saved nearly USD 1.6 trillion in healthcare costs in the US over the last decade. Given the cost benefits offered, generic medicines usually have high adoption rates. Moreover, upcoming patent expiries of several blockbuster drugs, such as LYRICA®, Cialis®, Advair® and Sensipar®, have intensified the interest of several drug manufacturers in the development of generics. As more generic drugs get approved by regulators across the globe, the competition in the industry has steadily increased. Interestingly, in 2018, the US FDA approved more than 780 generic products, which represented more than 90% increase in the number of such drug approvals since 2014. The most evident impact of the growth in competition in this domain is deflation of cost of generics, resulting in diminished profit margins for the developers of such products. Therefore, to ensure sustainable growth within the off-patent drug products market, companies are gradually adopting innovative drug alteration techniques in order to develop value added medicinal products, which offer better commercial benefits.
Scope of the Reports
The ‘Generics Market: Focus on Value-added Medicines / Supergenerics, 2019-2030’ report features an extensive study of supergenerics, as well as the current landscape and future potential of technology providers that are offering innovative platforms / solutions to supergeneric drug developers. Amongst other elements, the report features:
- An overview of recently approved supergenerics (over the period 2016-2018), featuring information on route of administration, target disease indication(s), target therapeutic area(s), approval timeline, submission classification code and most active drug developers (in terms of number of product approvals). Additionally, it provides a detailed assessment of technology providers, offering platforms / solutions for supergeneric drug development, including information on year of establishment, company size and geographical location.
- An informed competitiveness analysis of the technologies captured in our database, taking into consideration relevant parameters, such as supplier power (based on company size of technology provider) and other important technology-related specifications, such as the type of molecule, impact on drug properties and route of administration.
- Elaborate profiles of prominent technology developers engaged in this domain, featuring an overview of the company, its financial information (if available), a detailed description of its technology platform(s), recent developments and a comprehensive future outlook.
- A list of marketed generics that, we believe, are likely to be developed as supergenerics in the near future, based on an in-depth analysis taking into consideration multiple relevant parameters, such as the current annual cost of treatment of the parent drug, year of patent expiry, revenues generated in the year before patent expiry, target therapeutic area and number of competitor (generic) drugs available in the market.
For More Information Click under-
The applications of oligonucleotides are vast, even beyond the life science / pharma sector; however, owing to complexities associated with the synthesis and processing of these molecules, such operations are usually outsourced to capable CMOs Roots Analysis is pleased to announce the publication of its recent study, titled, “Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030.” The report features an extensive study of the current scenario and future potential of the custom synthesis, modification and purification services market for oligonucleotides, which are intended for research, diagnostic, and therapeutic applications.
The study includes in-depth analyses, highlighting the capabilities of service providers engaged in this domain.
In addition to other elements, it includes:A detailed review of the current status of the market with respect to oligonucleotide manufacturers focused on research and diagnostic, and therapeutic applications.A competitiveness analysis of prominent oligonucleotide manufacturers, featuring insightful pictorial summaries and representations.Elaborate profiles of key players that offer a diverse range of capabilities for custom synthesis, modification and purification of oligonucleotides.An analysis of the various partnerships pertaining to oligonucleotide manufacturing, which have been established in the recent past.An analysis of the various expansion initiatives undertaken by service providers engaged in this domain.A detailed analysis of completed, ongoing and planned clinical research studies of various oligonucleotide-based drug products.An estimate of the overall, annual capacity for manufacturing oligonucleotides based on data reported by industry stakeholders in the public domain.An informed estimate of the annual clinical and commercial demand for oligonucleotides.A discussion on affiliated trends, key drivers and challenges, under an elaborate SWOT framework.A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing custom synthesis, modification and purification services for oligonucleotides.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) To request for customize report – https://www.rootsanalysis.com/reports/304/request-customization.html Type of ManufacturingCustom ManufacturingLarge-scale ManufacturingType of Oligonucleotides ManufacturedAntisense OligonucleotidesmiRNAsshRNAssiRNAsOther OligonucleotidesScale of OperationClinicalCommercialPurpose of ProductionIn-houseOutsourcedTarget Therapeutic AreaAutoimmune DisordersCardiovascular DisordersGenetic DisordersInfectious DiseasesMetabolic DisordersNeuromuscular DisordersOncological DisordersOphthalmic DisordersOther Therapeutic AreasSize of manufacturerSmallMid-sizedLargeKey Geographical Region North AmericaEuropeAsia-Pacific and Rest of the WorldTo request for sample report – https://www.rootsanalysis.com/reports/oligonucleotide-synthesis/request-sample.html Transcripts of interviews held with the following senior level representatives of stakeholder companiesJoachim Bertram (Chief Scientific Officer and Managing Director, IBA Lifesciences)Tobias Pohlmann (Founder and Managing Director, BianoScience) Key companies covered in the reportAgilent TechnologiesAjinomoto Bio-Pharma ServicesBioSpringCordenPharmaIntegrated DNA TechnologiesKaneka EurogentecLGC Biosearch TechnologiesMicrosynthNitto Denko AveciaSigma AldrichThermo Fisher ScientificTrilink Biotechnologies For more information please click on the following link:https://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.html Other Recent OfferingsChina Biopharmaceutical Contract Manufacturing Market, 2020-2030Pharmaceutical Continuous Manufacturing Market, 2020-2030Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.
The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected] - https://www.facebook.com/RootsAnalysisLinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/Twitter - https://twitter.com/RootsAnalysis
The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated to offer lucrative opportunities to service providers serving this niche, but growing market segment London Roots Analysis has announced the addition of the “Microbial Contract Biomanufacturing Market, 2020-2030” report to its list of offerings.
Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly.
Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics.
Europe is currently regarded as a key manufacturing hub for microbial biologicsThere are more than 150 manufacturing facilities, with microbial fermentation capabilities, worldwide; of these, 43% are in Europe, followed by North America (31%).
On the other hand, prominent regions in the Asia Pacific and Middle East, where microbial biologics are manufactured, include (in decreasing order of number of resident manufacturing facilities) China, India, Japan, Australia and Israel.
Further, a large number (~25%) of the partnerships were observed to be focused on the production of microbial biologics; this is followed by process development and manufacturing agreements (20%).
Therefore, the use of technology can save time and money, while providing a far better understanding of the relationships between different formulations and processes parameters.Key Drivers, Restraints, and Opportunities of AI in Pharma and Biotech MarketAdoption of artificial intelligence (AI) in the drug discovery market in developing regions such as APAC is increasing, thanks to the expansion of pharmaceutical industries by collaborating with other industries and rise in demand to reduce drug discovery time.
Furthermore, the expansion of biotechnology industries is estimated to offer significant opportunities for the market.An estimated 50% of U.S. citizens are affected by at least one chronic condition; consequently, the pharmaceutical segment of the healthcare industry is projected to be positively impacted by the expected trend of AI adoption.All top 10 so-called giant pharma companies (namely Novartis, Roche, Pfizer, Merck, AstraZeneca, GlaxoSmithKline, Sanofi, Abbvie, Bristol-Myers Squibb, and Johnson & Johnson) have either expressly collaborated with or acquired AI technologies to take advantage of the opportunities AI brings to the table.
Industry leaders are presently focused on the development of more efficient methods, and machine learning is emerging as a possible solution.The current machine learning initiatives of the top five pharmaceutical and biotechnology companies reveal trends within the following areas:Digital coaching solutions – Utilization of web-based technologies to simulate one-on-one coaching sessions so that all patients can have the benefit of a uniquely devised medication program.For instance: Johnson & Johnson’s Patient Athlete programPersonalized medicine – Personalized medicine, also called precision medicine, maybe a medical model that separates people into different groups—with medical decisions, practices, interventions, and/or products being tailored to the individual patient supported their predicted response or risk of disease.For instance.
Unlike other applications within healthcare facilities, drug discovery seems to own a clearer path to adoption.Recently, robots became more collaborative with humans and are more easily trained by moving them through the desired task.
Over time, it seems likely that an equivalent improvement in intelligence that we have seen in other areas of AI would be incorporated into physical robots.Surgical robots initially approved in the U.S. in 2000, provided ‘superpowers’ to surgeons, improving their ability to examine, create precise and minimally invasive incisions, and stitch wounds.
Common surgical procedures using robotic surgery include gynecologic surgery, prostate surgery, and head and neck surgery.Pre Book Ai In Pharma And Biotech Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=79399=S North America to Capture Major Share of Global Market of AI in Pharma & BiotechNorth America is expected to account for a major share of the global market of AI in Pharma and Biotech due to the high prevalence of chronic diseases among the population.
Softcon Systems brings you automation solutions specific to the pharmaceutical industry – we will work with you to develop and implement ideal solutions specific to your requirements.
Automation at every point of the value chain will enable the pharma companies to get pharmaceuticals from the lab to the patient more quickly.We design systems that help pharmaceutical and biotech companies to achieve operational excellence, reduce time to market and meet all industry standards and regulations.
